Local view for "http://purl.org/linkedpolitics/eu/plenary/1999-10-05-Speech-2-202"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.19991005.10.2-202"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"In response to that question, you will be aware that the precautionary principle operates in circumstances where there is either no scientific evidence available or where the evidence that is available is uncertain in character.
That is not the situation here. The report that I referred to, that was published by the SCVPH in April this year, specifically identified that there were residues of one of the six particular hormones that were being checked for – that is, 17 beta-estradion. That particular hormone is found in 80% of the tests that have been carried out. This particular hormone is – as described by the committee – clearly a carcinogen.
Having regard to these circumstances it is believed that the lifting of the ban at this stage would be premature. Accordingly, having regard to what I said earlier about the application of the precautionary principle, it seems to me that it would be inappropriate to apply that principle because there is clear evidence available to us from the report from the SCVPH.
In relation to our negotiations with the WTO, this issue will have to be addressed. There has been United States representation on the committee that conducted the examinations. That will be stressed to the US negotiators. This is an important issue. It is one that has to be addressed between the United States and the European Union. One would hope that it would be addressed in an amicable and non-confrontational manner. Hopefully that will be done during the WTO negotiation period."@en1
|
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples